BMRN vs HAVAR
Biomarin Pharmaceutical Inc (BMRN) versus Harvard Ave Acquisition Corporation Rights that convert on a 1/10th of 1 basis to Class A ordinary Shares (HAVAR) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Harvard Ave Acquisition Corporation Rights that convert on a 1/10th of 1 basis to Class A ordinary Shares (HAVAR) common stock listed on NASDAQ.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
HAVAR does not have a complete income-statement cache yet.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. HAVAR currently screens at market cap $0.
Not investment advice. Open the BMRN and HAVAR stock pages for the full models.
Not investment advice.